Health Care Delivery

Nimbus Therapeutics and Eli Lilly announce their partnership to develop a novel oral drug for patients with obesity and other metabolic disorders.

GoodRx offers affordable access to oral semaglutide for weight loss through telemedicine, simplifying treatment options and pricing for consumers.

Reader favorites from the 2025 Patient-Centered Oncology Care conference included articles and interviews featuring AI's role in precision medicine and the importance of collaboration in delivering care.

New treatments, care gaps, and cardiac monitoring were major focuses in cardiovascular news this year.

Our top 5 obesity articles of 2025 highlight GLP-1 prescribing trends, insurance coverage, co-pay caps, real-world use, and access challenges.

New therapies and individualized care plans for menopausal women highlighted the most-read 2025 SABCS coverage.

These are the most popular multiple myeloma articles from 2025.

Our top dermatology content of 2025 highlights AI wearables, new biologics, emerging vitiligo treatments, and strategies for rare and complex skin diseases.

Here are our top highlights from AAD 2025 that include safety of topical JAK inhibitors, climate impacts on skin health, affordability of classic therapies, and advancing AI in dermatology.

Patients with generalized myasthenia gravis face significant barriers to diagnosis, creating the need for improved patient–health care interactions.

Our top 5 heart failure content of 2025 include FDA approvals, GDMT optimization, risk markers like LBBB and SDOH, and value-based care models improving outcomes in heart failure.

Heart failure deaths increasingly occur at home or in hospice, but racial, sex, and regional disparities persist in end-of-life care.

The cardiac myosin inhibitor is expected to be available in the US in the second half of January 2026.

Discover the latest breakthroughs in myasthenia gravis treatment, including rozanolixizumab and nipocalimab, and insights on disease burden and dysphagia indicators.

Trump secures new pricing deals with 9 drugmakers, advancing his effort to align US drug costs with Europe and expand direct-to-consumer purchasing.

Limiting health-related social needs screening to lower-income areas would reduce screening burdens; however, this study found a 2-stage screening approach based on geography to be suboptimal.

A phase 2b trial found vixarelimab rapidly reduced itch and lesion burden in prurigo nodularis, with sustained benefit and a favorable safety profile.

New research reveals that quick sleep onset may lower hypertension risk, challenging traditional views on sleepiness and cardiovascular health.

Reflect on the challenges in health equity, care access, and policy shifts impacting health insurance and clinical research in 2025.

Intranasal etripamil was approved to self-treat episodes of paroxysmal supraventricular tachycardia, supported by phase 3 RAPID trial data.

A new study finds patients with unmet social needs like housing or transportation face higher ED and inpatient use and that resolving these needs may reduce utilization.

The foundation of medically integrated pharmacy includes 7 critical pillars. This commentary focuses on the benefits of 3 of those pillars: abandonment, adherence, and access/affordability.

AHA 2025 highlights included new guidelines and targeted approaches advancing heart failure and cardiovascular care.

Blinatumomab enhances survival in pediatric B-cell ALL, yet homecare challenges hinder its outpatient delivery.

Pediatric atopic dermatitis advances, ruxolitinib safety, IgE insights, and more at the Society for Pediatric Dermatology (SPD) 2025 meeting.